Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications
Results suggest that MYC overexpressing cancers can be targeted by exploiting ribosome heterogeneity in cancer; preclinical data demonstrated activity of ZKN-157 against subtypes of colorectal cancer
Research potentially opens large opportunities to selectively target MYC-driven cancers with a novel mechanism and possible synergy with existing cancer therapies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.